![[SER140]-PLP(139-151) TFA](/upload/1124/V77337.png)
| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| Other Sizes |
| Targets |
Myelin proteolipid protein (PLP). The (SER140)-PLP(139-151) peptide corresponds to a well-characterized epitope of PLP, the most abundant protein in central nervous system myelin. In EAE models, this peptide is recognized by autoreactive T cells, leading to their activation, proliferation, and subsequent infiltration into the CNS, which triggers inflammatory demyelination and mimics the pathology of multiple sclerosis. This makes the peptide a crucial tool for studying T cell responses in autoimmune demyelination.
|
|---|---|
| ln Vitro |
The peptide is used to elicit and characterize antigen-specific T cell responses in vitro. It is a critical tool for inducing T cell proliferation, cytokine secretion (e.g., IFN-gamma, IL-17), and phenotypic changes in T cells isolated from immunized animals. The peptide's specific sequence and immunogenic properties allow for the reproducible activation of T cell clones, enabling researchers to study the mechanisms of antigen recognition, tolerance, and immune regulation within the CNS.
|
| ln Vivo |
In vivo, [SER140]-PLP(139-151) TFA is extensively used to induce experimental autoimmune encephalomyelitis (EAE), a well-established animal model for multiple sclerosis. By administering the peptide in combination with complete Freund's adjuvant (CFA) and pertussis toxin, investigators reproducibly trigger CNS-directed autoimmunity, allowing for the evaluation of disease onset, progression, and the efficacy of therapeutic interventions.
|
| Enzyme Assay |
For non-cell binding assays, the affinity of the peptide for MHC class II molecules can be assessed. A typical MHC class II-peptide binding assay involves incubating purified MHC class II molecules (e.g., I-As or I-Au) with a fluorescently-labeled reference peptide and varying concentrations of the test peptide. After incubation at 37degC for 24-48 hours to reach equilibrium, the fraction of bound ligand is measured using a fluorescence polarization (FP) reader or size exclusion chromatography. The IC50 is calculated from dose-response curves.
|
| Cell Assay |
For T cell activation assays, splenocytes or lymph node cells isolated from EAE-induced animals are seeded in 96-well plates. These cells are stimulated with varying concentrations of [SER140]-PLP(139-151) TFA (typically 1-100 ug/mL) for 48-72 hours. T cell proliferation is measured by [3H]-thymidine incorporation or by flow cytometry using CFSE dilution. Cytokine levels (IFN-gamma, IL-17, IL-4) in the supernatant are quantified by ELISA to assess the Th1/Th17 response. This ex vivo restimulation protocol is standard for evaluating T cell recall responses.
|
| Animal Protocol |
The induction of EAE in female SJL/J mice is the standard in vivo protocol. Mice are immunized subcutaneously with an emulsion of [SER140]-PLP(139-151) TFA (100-200 ug/mouse) in complete Freund's adjuvant (CFA) supplemented with Mycobacterium tuberculosis. Additionally, pertussis toxin (200-500 ng/mouse) is administered intraperitoneally on days 0 and 2 post-immunization. Mice are monitored daily for clinical signs of EAE (tail limpness, hind limb paralysis) and scored on a standard 0-5 scale. At the endpoint (typically days 14-30), spinal cords are collected for histopathological analysis of demyelination and immune cell infiltration.
|
| ADME/Pharmacokinetics |
As a peptide, the TFA salt form is highly soluble in H2O (~100 mg/mL). For in vivo EAE induction, the peptide is typically dissolved in PBS and emulsified with CFA. Peptides generally have short plasma half-lives (minutes to a few hours) due to rapid proteolytic degradation. The TFA counterion aids in solubility but does not enhance metabolic stability. The peptide must be stored as a lyophilized powder at -20degC to prevent degradation; the stock solution should be stored at -80degC.
|
| Toxicity/Toxicokinetics |
The toxicity of [SER140]-PLP(139-151) TFA itself is associated with its role in inducing autoimmune pathology. In EAE models, administration of the peptide leads to weight loss, paralysis, and CNS inflammation as a measure of disease, which can be severe depending on the dose. At the standard doses used for EAE induction (100-200 ug/mouse), the peptide is not systemically toxic to healthy tissues, but it induces severe autoimmune pathology in susceptible mouse strains. The TFA salt is not toxic at these concentrations.
|
| References |
[1]. Kordopati GG, et al. Biologically relevant conformational features of linear and cyclic proteolipid protein (PLP) peptide analogues obtained by high-resolution nuclear magnetic resonance and molecular dynamics. J Comput Aided Mol Des. 2017 Jul 29.
|
| Additional Infomation |
[SER140]-PLP(139-151) TFA is a research-grade chemical widely used in neuroimmunology and multiple sclerosis research. It is the primary tool for studying the pathogenesis of demyelinating diseases, providing critical insights into T cell-mediated autoimmunity. It has been used in high-resolution NMR and molecular dynamics studies to investigate the biologically relevant conformational features of linear and cyclic PLP peptide analogues. This product is for research use only (RUO) and is not a clinical drug; it has no FDA approval or clinical trial status.
|
| Molecular Formula |
C74H105F3N20O19
|
|---|---|
| Molecular Weight |
1635.74
|
| Related CAS # |
[SER140]-PLP(139-151);122018-58-0
|
| Appearance |
White to off-white solid powder
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O :~100 mg/mL (~61.13 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 100 mg/mL (61.13 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with sonication.
(Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 0.6113 mL | 3.0567 mL | 6.1134 mL | |
| 5 mM | 0.1223 mL | 0.6113 mL | 1.2227 mL | |
| 10 mM | 0.0611 mL | 0.3057 mL | 0.6113 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
